Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

The Journal Headache reports that electroCore’s nVNS is an effective bioelectric medicine for episodic cluster headache

September 12, 2016 By Abigail Esposito

headaches

The paper also reported that nVNS is well tolerated, produced no serious side effects and that the percentage of episodic patients who experienced a successful response to the first attack treated within 15 minutes was triple that of those using the sham: 34.2% versus 10.6% (p<0.01).

In a multi-centered, sham-controlled study conducted in the U.S., episodic cluster headache patients using the gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of the treatment of the attack, as compared with the sham treatment, and that this benefit was sustained for over an hour.

The paper also reported that nVNS is well tolerated, produced no serious side effects and that the percentage of episodic patients who experienced a successful response to the first attack treated within 15 minutes was triple that of those using the sham: 34.2% versus 10.6% (p<0.01).

After an hour all subjects in the gammaCore group had maintained their successful response. The study also found consistency of effect among responders, with the percentage of episodic subjects in the active arm who experienced success for more than 50% of the attacks was 34.2% versus 14.9% among the sham group (p=0.04).

The study (ACT 1) was one of the largest ever undertaken in cluster headache, one of the worst pain conditions know to medicine, and it was carried out in the US enrolling 150 patients at 20 headache treatment centers.

Patients were divided into two arms during the randomized period: one using a sham device and the other using the gammaCore nVNS device. Patients self-administered the therapy by placing the sham or gammaCore on the skin over the vagus nerve in the neck.

This new treatment has been welcomed by cluster sufferers and clinicians as there are limited therapeutic options for the acute treatment of cluster headache, which afflicts more than 300,000 people in the U.S. In the U.S., only subcutaneous sumatriptan injections and intravenous DHE are approved for acute use; however, DHE is limited to hospital use and the FDA approved labeling for sumatriptan allows a maximum of two doses per day.

As a result, there is a significant unmet need for many patients, including those with frequent attacks–3 to 8 attacks a day–who cannot use injectable sumatriptan to treat every attack due to a separate condition known as medication overuse headache which can be caused by repeated use of triptans.

Following the completion of the double-blind period, the ACT 1 trial included a three-month open label phase during which all patients were permitted to use gammaCore. The results for all the episodic patients–those previously on sham and those previously on gammaCore–were in line with the results from the double blind phase, i.e., patients who had previously used the sham device experienced a significant increase (nearly 2.5 times) in successful responses.

Patient preference was also measured, and over 90% of the patients found the gammaCore device easy to use and most reported they would recommend it to a family member or friend. A similar study is presently being conducted in the EU and will report shortly.

The Journal Headache
onlinelibrary.wiley.com

ElectroCore
electrocore.com

Related Articles Read More >

Theranica lands VA contract for migraine device
FDA clears Theranica device for adolescent migraines
cleveland-clinic-disruptors-2021
The top 10 medical disruptors of 2021
Trial: Cefaly wearable safe, effective in preventing migraines

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech